ALEXANDER FLEMING SA

Their core work

Alexander Fleming SA is an Argentine private organization based in Buenos Aires that participates in international cancer research consortia, contributing clinical expertise and access to Latin American patient populations. Their work sits at the intersection of oncology, epidemiology, and clinical care, with documented involvement in rare tumor research (sarcomas) and personalized approaches to gastric cancer. As a non-European participant in H2020 Research and Innovation Actions, they serve as a bridge between EU research networks and South American clinical infrastructure — a role that provides consortia with geographic and demographic diversity that European-only studies cannot replicate. Their funding profile suggests they function as a specialist clinical partner rather than a methodological or technical lead.

What they specialise in

How they've shifted over time

Both H2020 projects started in the same year (2019), so a true longitudinal evolution is difficult to establish — the "early vs. recent" keyword split reflects thematic breadth across simultaneous projects rather than a chronological shift. That said, the thematic arc is visible: SELNET anchors their work in rare tumor clinical care and diagnosis (a clinician's perspective), while LEGACy pushes toward data-intensive omics epidemiology and personalized medicine (a translational research perspective). This suggests Alexander Fleming SA is either expanding its internal capabilities toward molecular data methods, or is deliberately positioning itself in consortia that move from disease description toward treatment personalization.

Their dual participation in both a rare-tumor clinical network and an omics-driven personalized medicine consortium suggests a trajectory toward data-rich, precision oncology research — making them a useful partner for future consortia combining clinical cohorts with molecular profiling.

How they like to work

Alexander Fleming SA has participated exclusively as a consortium partner — never as coordinator — across both H2020 projects. Their network of 21 partners across 13 countries in just two projects indicates they integrate into large, geographically distributed consortia rather than small bilateral arrangements. This points to a specialist contributor role: they bring something specific (likely clinical access or Latin American patient cohorts) that large EU-LATAM research networks need, without taking on project management or coordination responsibilities.

Despite only two projects, Alexander Fleming SA has accumulated 21 unique consortium partners across 13 countries — an unusually wide network for such a small H2020 footprint. Both projects are explicitly structured as EU-LATAM collaborations, reflecting a consistent geographic bridge role between European research institutions and South American clinical sites.

What sets them apart

Alexander Fleming SA occupies a rare position: an Argentine private organization embedded in H2020 health research consortia, which is uncommon given that most H2020 third-country participants are universities or public research institutes. Their value to consortium builders lies in providing access to Latin American clinical populations and regional networks — specifically for cancers (sarcoma, gastric cancer) where epidemiological data from LATAM differs meaningfully from European cohorts. For any European research team seeking to build a genuinely intercontinental oncology study, this organization represents a ready-made entry point into Argentine clinical infrastructure.

Highlights from their portfolio

• SELNET
  The larger of the two grants (EUR 194,400) and the flagship project linking European and Latin American institutions to improve sarcoma diagnosis — a rare cancer area with very few dedicated international networks.
• LEGACy
  Represents a methodological step forward — applying omics integrative epidemiology to gastric cancer within a CELAC-Europe framework, signaling engagement with precision medicine methods beyond purely clinical research.